Collectively, TAA-targeting IgE mAbs may drive a unique monocyte and macrophage polarisation signature, which combined with an alternative tumour killing mechanism and superior in vivo anti-tumour activity, may permit sustained efficacy, which has hitherto eluded TAA-targeting IgG mAbs in ovarian cancer. The gene discussed is IGHE; the disease is ovarian cancer.